Canagliflozin in Patients With Acute Decompansted Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

Also called NCT05364190

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05364190
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05364190. Randomized; no masking; primary purpose treatment. Start 2022-06-04 (actual); primary completion 2023-12-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Canagliflozin in Patients With Acute Decompansted Heart Failure
Acronym
The CANA -AHF
Condition
Chronic Heart Failure
Condition
Acute Heart Failure
Condition
Diabetes Mellitus
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Empagliflozin
Lead sponsor
October 6 University (class: other)
Collaborator
Cairo University (class: other)
Collaborator
National Heart Institute, Egypt (class: other government)

Record details

Record id
cardio:ct-nct05364190
Content hash
e70d6bab7438f684088a16000af4e7ee22318a3cde89cb8eef1749b573b80b55